8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 27, 2026·SEC
Q32 Bio Inc.(QTTB)Earnings, Financials & Key Ratios
QTTB•NASDAQ
$13.62
5.6× P/E·Price updated Jul 7, 2026
AboutQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Show more
- Revenue$54M
- EBITDA$17M+126.4%
- Net Income$30M+162.5%
- EPS (Diluted)2.42+136.8%
- Gross Margin99.27%
- EBITDA Margin32.18%
- Operating Margin31.45%
- Net Margin55.49%
- ROE125.06%+114.9%
QTTB Price & Volume
Q32 Bio Inc. (QTTB) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Underlying Clinical Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
Key Thesis Takeaways
- Q32 Bio remains a high-risk, clinical-stage entity whose financial profile is defined by extreme revenue volatility and persistent operational cash outflows.
- While the company achieved a $53.7M revenue spike in 2025Q4, this event was non-recurring, leaving the firm reliant on future clinical milestones to fund its ongoing R&D programs.
- Investors should remain cautious as the company's liquidity, currently at $50.8M in cash as of 2026Q1, faces continued pressure from high-cost development cycles and potential future dilution.
Verdict Logic
the firm's reliance on sporadic milestone payments and a persistent cash burn, evidenced by a $6.3M operating cash outflow in 2026Q1, suggests significant long-term liquidity risk.
QTTB Growth Metrics
Q32 Bio Inc. (QTTB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years81.85%
3 Years100.66%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM155.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM153.85%
Return on Capital
10 Years-73.34%
5 Years-88.04%
3 Years-118.86%
Last Year26.77%
QTTB Recent Earnings
Q32 Bio Inc. (QTTB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 1/12 qtrs (25%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.54-3.8%
$0.52
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$3.65+529.4%
$0.85
Rev
$54M+0.0%
$54M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.60+56.8%
$1.39
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.78+31.6%
$1.14
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.54vs $0.52-3.8% | — |
| Q2 2026 | Mar 10, 2026 | $3.65vs $0.85+529.4% | $54Mvs $54M+0.0% |
| Q4 2025 | Nov 13, 2025 | $0.60vs $1.39+56.8% | — |
| Q3 2025 | Aug 6, 2025 | $0.78vs $1.14+31.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Q32 Bio Inc. (QTTB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.62 | $174.01M | 5.63 | — | 55.49% | 125.06% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $3.10 | $505.47M | -1.89 | — | — | -131.58% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — |
Compare QTTB vs Peers
Q32 Bio Inc. (QTTB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QTTB SEC Filings & Documents
Q32 Bio Inc. (QTTB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when QTTB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QTTB Frequently Asked Questions
Q32 Bio Inc. (QTTB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Q32 Bio Inc.'s revenue?
Q32 Bio Inc. (QTTB) reported $53.7M in revenue for fiscal year 2025.
Is QTTB profitable?
Yes, Q32 Bio Inc. (QTTB) is profitable, generating $33.2M in net income for fiscal year 2025 (55.5% net margin).
Dividend & Returns
What is QTTB's return on equity?
Q32 Bio Inc. (QTTB) has a return on equity (ROE) of 125.1%. This is excellent, indicating efficient use of shareholder capital.
What is Q32 Bio Inc.'s free cash flow?
Q32 Bio Inc. (QTTB) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.